Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Xipni (02583) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] - The inclusion of Xipni in the index may lead to its eligibility for the Hong Kong Stock Connect, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - Xipni reported a preliminary review of its unaudited consolidated management accounts for the 11 months ending November 30, 2025, indicating a net profit exceeding RMB 90 million, which is an increase compared to the net profit of approximately RMB 49 million for the year ending December 31, 2024 [1] Group 2 - The expected growth in net profit for Xipni for the year ending December 31, 2025, is primarily driven by an increase in sales revenue from jewelry and an improvement in the gross margin from watch sales [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Xirui (02507) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC's research report, Xirui is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Western Securities (002673) noted that Xirui launched the VisionJet G3 product on February 3, with continuous price increases and upgrades in intelligence and comfort [1] - The firm believes that with the gradual acquisition of new orders for better-structured products like VisionJet G3 and SRG7+, the overall product structure will improve year-on-year, enhancing profitability [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with OSL Group (00863) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, OSL Group is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - OSL Group previously announced an expected net loss from continuing operations of approximately HKD 370 million to HKD 430 million for the fiscal year ending December 31, 2025, compared to a profit of approximately HKD 55 million for the fiscal year ending December 31, 2024 [1] - The anticipated loss is attributed to significant investments made by the group to establish a solid foundation for future growth [1]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, including the inclusion of LeShuShi (02698) in the Hang Seng Composite Index, effective March 9, 2026 [1] Company Overview - LeShuShi is a multinational hygiene products company focused on rapidly developing emerging markets in Africa, Latin America, and Central Asia, primarily engaged in the development, manufacturing, and sales of baby diapers, baby pull-ups, sanitary napkins, and wet wipes [1] - The company operates under several brands, including Softcare, Veesper, Maya, Cuettie, and Clincleer, with product sales covering over 30 countries in West Africa, East Africa, and Central Africa [1] - A significant portion of the company's revenue during the historical period came from sales to African customers [1] Market Implications - The inclusion of LeShuShi in the Hang Seng Composite Index may lead to its potential addition to the Hong Kong Stock Connect, as it meets various criteria such as market capitalization, liquidity, and listing duration [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Zhonghui Biotech-B (02627) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC research, Zhonghui Biotech-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - Zhonghui Biotech-B announced that the National Medical Products Administration of China has approved its new drug application for a trivalent influenza virus subunit vaccine for all age groups [1] - This vaccine is the first and only fully approved trivalent influenza virus subunit vaccine for the entire population in China [1] - The product represents a significant upgrade over traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Valiant Bio-B (09887) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Valiant Bio-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Valiant Bio-B announced that the first patient has successfully received treatment in the Phase Ib/II clinical study of its PD-L1/4-1BB bispecific antibody, Opalizumab (LBL-024), for recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted simultaneously at multiple hospitals across the country [1] - The trial aims to evaluate the efficacy and safety of Opalizumab as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Jinfang Pharmaceutical-B (02595) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC's research report, Jinfang Pharmaceutical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - CMB International recently initiated coverage on Jinfang Pharmaceutical, giving it a buy rating with a target price of HKD 51 [1] - Jinfang Pharmaceutical is characterized as an innovative pharmaceutical company rooted in mainland China with a global perspective, supported by a core management team averaging over 20 years of industry experience [1] - The company has established a drug pipeline that includes six clinical-stage candidate drugs [1]

Core Viewpoint - The Hang Seng Index Company announced the inclusion of Xipuni (02583) in the Hang Seng Composite Index, effective March 9, 2026, following a quarterly review, which may also lead to its inclusion in the Stock Connect program due to meeting various criteria [1] Group 1: Company Performance - Xipuni reported a preliminary net profit exceeding RMB 90 million for the 11 months ending November 30, 2025, indicating a significant increase compared to a net profit of approximately RMB 49 million for the year ending December 31, 2024 [1] - The expected growth in net profit for Xipuni is attributed to an increase in sales revenue from jewelry and an improvement in the gross margin from watch sales [1]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Jiaxin International Resources (03858) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Company Performance - Jiaxin International Resources is expected to turn a loss into a profit, projecting a net profit attributable to shareholders of approximately HKD 300 million to HKD 340 million for the year ending December 31, 2025, compared to a net loss of HKD 173 million for the year ending December 31, 2024 [1] - The anticipated turnaround is primarily due to the group not generating any revenue in 2024 as it had not commenced operations, leading to the reported loss [1] Group 2: Market Impact - The inclusion of Jiaxin International Resources in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - The adjustments to the eligible stocks for the Hong Kong Stock Connect will be made accordingly by the Shanghai and Shenzhen stock exchanges [1]

Core Viewpoint - The Hang Seng Index Company announced the results of the quarterly review for the Hang Seng Index series, with Innovation Industry (02788) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Information - Innovation Industry was officially listed on the Hong Kong Stock Exchange on November 24, 2025, with an issue price of HKD 10.99 per share, raising approximately HKD 5.5 billion [1] - The company attracted 17 well-known cornerstone investors, including Hillhouse, China Hongqiao, Taikang Life, Jinglin, Orix, China Pacific Insurance, GF Fund, and Winton Fund, with a total subscription amount of approximately USD 351 million, indicating strong institutional investor confidence in its fundamentals [1] Group 2: Market Impact - The inclusion of Innovation Industry in the Hang Seng Composite Index may lead to its potential addition to the Hong Kong Stock Connect, as it meets various criteria including market capitalization, liquidity, and listing duration [1] - The adjustment in the eligible stocks for the Hong Kong Stock Connect will be made accordingly by the Shanghai and Shenzhen Stock Exchanges [1]